TRANSPERFECT
LIFE SCIENCES

The Imperative of Automation in Pharmacovigilance and Patient Safety

AI/ML-POWERED TRANSFORMATION IN PV AND SAFETY PROGRAMS

THE IMPERATIVE OF AUTOMATION IN PHARMACOVIGILANCE AND PATIENT SAFETY

AI/ML-Powered Transformation in PV and Safety Programs

Discover the transformative potential of tech-enabled pharmacovigilance (PV) to maximize patient safety and streamlined reporting. This overview details the practical application of Artificial Intelligence (AI), Translation Management Systems (TMS), and other innovative solutions that are revolutionizing critical work streams. Equip your organization with strategies that improve patient safety, reduce risk, maintain compliance, expedite processes, and reduce operational cost.

TABLE OF CONTENTS

Navigate to the section that interests you most.

INTRODUCTION

On the frontlines of patient safety and public health, pharmacovigilance (PV) stands as a critical safety function in clinical development and post-market activity. Upholding safety standards in the face of evolving regulations ensures processes remain compliant and mitigates launch delays.

Regulatory authorities enforce strict timeline requirements, such as the FDA's mandatory 15-day post-market reporting requirement for unexpected serious suspected adverse events (USSAEs)[1], which often leaves no room for flex or error. In this respect, a delay or inaccuracy in reporting could amount to hefty penalties and sanctions, setting teams back exponentially in their time to launch.

For global studies, this also means adhering to multilingual reporting requirements. Safety data must be translated into the official language of the country where the information is submitted, as mandated by many regulatory bodies. With already tight reporting timelines, maximizing efficiencies in translation accuracy, quality, and turnaround time is essential.

The industry has evolved in tandem with these stringent requirements to develop infrastructures that seamlessly manage the volume of safety reporting. Optimized PV processes harness the power of technological advancements, such as Artificial Intelligence (AI), to create a synergy between receiving, onboarding, and implementing regulatory guidance in safety workflows. To this end, strategic integration of data analytics, automated monitoring tools, and AI-powered translation have revolutionized PV and safety practices, empowering teams with enhanced precision and speed to address and report on safety issues.

TRANSFORMING PV AND SAFETY PROGRAMS

The evolving landscape of pharmacovigilance demands a strategic fusion of technology and expert services to streamline safety case management and maintain a competitive edge. As the complexity and volume of safety cases grow in tandem with global clinical advancements, pharmaceutical organizations grapple with the challenge of effectively leveraging technology to enhance existing workflows. Effective PV and safety programs provide the following outcomes:

- **Enhanced Patient Safety:** With the integration of cutting-edge technologies and specialized services, sponsors can detect adverse events early, ensuring prompt interventions and rapid dissemination of safety data. This proactive approach significantly reduces risks and prioritizes patient safety, ensuring they receive optimal care with minimal side effects[2].
- **Regulatory Compliance:** Meeting regulatory requirements goes beyond mere compliance. An efficient PV strategy ensures timely submissions, adapts to varying reporting timelines based on adverse event (AE) severity, and instills trust with regulatory bodies[3].
- **Cost Savings:** While investing in advanced PV solutions requires an initial outlay, the long-term returns — from reduced product recalls to minimized compliance penalties — eclipse the initial costs. By streamlining operations and harnessing AI-powered systems, sponsors can significantly curtail manual labor costs and elevate the quality of safety reporting[4, 5].
- **Operational Efficiency:** The adoption of AI/ML technologies automates routine tasks, freeing up human resources for more intricate analytical tasks. Introducing automation, such as in data entry and literature monitoring, can accelerate the case routing process by up to 75%[6], ensuring accuracy and optimal resource allocation[7, 8].

- **Data-Driven Insights:** Amid the deluge of data in PV, drawing actionable insights is a daunting task. However, a solid technological strategy aids in data mining, predictive analytics, and pattern recognition, offering invaluable insights that can shape drug development, post-marketing surveillance, and even marketing initiatives[9].
- **Global Collaboration:** As adverse events in one region can reverberate globally, fostering international collaboration is paramount. Effective PV strategies prioritize real-time safety data sharing, enabling global health entities to act cohesively, thereby standardizing safety protocols and fostering a collaborative patient safety culture[10].
- **Strengthened Reputation:** Beyond compliance, an effective PV strategy enhances trust among patients, healthcare professionals, and the wider public. By consistently upholding safety standards, adopting risk management frameworks, and ensuring transparency, sponsors can enhance their market position and brand image[11].

In summary, embracing a comprehensive PV and safety strategy offers many benefits, from safeguarding patient well-being to financial gains, underscoring the transformative potential of such an approach. PV and safety programs do more than adhere to regulatory compliance; they spearhead patient safety and set industry benchmarks[12, 13].

BUSINESS CASES FOR OPTIMIZING PV AND SAFETY WORKFLOWS

To achieve successful outcomes like the ones highlighted above, consider business cases and opportunities for optimization. Potential avenues for PV and safety workflows include process automation, data analysis, and system interoperability. Below are some of the key business cases for enhancing your PV capabilities:

- **Real-Time Tracking for Adverse Event Monitoring:** The nature of pharmaceutical, biotechnology, and medical device innovation is increasingly complex. This complexity translates to an increased risk of unexpected AEs. Real-time monitoring is not just a technological advancement; it is a safety imperative. Real-time monitoring ensures that any AEs are immediately identified, analyzed, and submitted to the appropriate authority in the mandated turnaround time. This prompt response not only safeguards patient safety, but also adheres to regulatory requirements, mitigating compliance risk or subsequent launch delays. Moreover, with healthcare professionals and patients requiring on-demand medical information, the expectation for the industry to provide real-time monitoring is higher than ever[14].
- **Early Detection for Product Recalls:** In the pharmaceutical industry, the cost of recalling a product goes beyond finances; it also impacts brand reputation and trust. Early detection systems, powered by sophisticated data analytics, can identify potential issues before they escalate, enabling companies to take corrective measures proactively. This early intervention can prevent widespread product recalls, thereby mitigating both financial losses and reputational damage. Moreover, in a landscape where regulators are increasingly vigilant, the ability to proactively address issues reinforces a company's commitment to patient safety and regulatory adherence[15].
- **Safety Reporting Automation:** Manual safety reporting is laborious and prone to human error. Automated safety reporting systems protect accuracy and consistency while boosting efficiency. Such systems ensure that company's capture, analyze and report safety data in a standardized manner, minimizing discrepancies. For teams managing immense volumes of safety reporting data, automation in this capacity can be transformative for timely and accurate safety reporting. Furthermore, with the increasing regulatory scrutiny and the high costs associated with non-compliance, automated reporting becomes a pivotal tool in a company's PV arsenal[16].

- **Integration of Diverse Data Sources:** With the variety of PV data, integrating information from different sources becomes a significant challenge. However, companies cannot afford to sidestep this challenge. Integrating data from clinical trials, real-world evidence, patient reports, and other sources provides a more complete view of drug safety. This data consolidation is crucial for accurate risk assessment, ensuring that decisions are based on the entirety of available data rather than isolated datasets[17]. Operating in a streamlined system designed to harmonize data from various sources facilitates a holistic view of safety cases. An example would be integration of safety databases (Aris Global, Argus, etc.) with a Translation Management System.
- **Enhanced Analytics for Post-Marketing Surveillance:** After market approval, organizations are mandated to monitor stringently for safety reporting and provide channels for patients to report their experiences of AEs. However, monitoring all prospective channels can be an unwieldy task. Powered by advanced analytics, post-marketing surveillance allows for continuous monitoring of their product safety in diverse patient populations. Services such as AI-powered literature monitoring[18] and social listening can grab and parse insights about drug safety from a variety of external publications and media channels. This continuous monitoring is essential to detect adverse events, understand long-term drug effects, and ensure that the benefit-risk profile of the drug remains favorable[19].

In summary, real-time monitoring, automation, and advanced analytics are essential advancements that uphold drug safety standards in an increasingly complex industry. Adopting such innovations will define industry excellence moving forward.

TECHNOLOGY & SERVICES TO OPTIMIZE PV AND SAFETY WORKFLOWS

The rapid growth of safety case volumes and the global demand for cutting-edge, clinical advancement leaves pharmaceutical organizations to face the question: *How can I best harness the power of technology to optimize my existing workflows and maintain a competitive edge in this shifting landscape?*

- **Artificial Intelligence/Machine Learning:** AI/ML offer vast data processing and analytical capabilities to analyze large datasets swiftly. McKinsey projects that Generative AI (Gen AI) could unlock a value between $60bn to $110bn annually for the pharma industry[20]. To this end, AI can significantly enhance the PV process, with use cases in data extraction, signal detection from integrated data, automated case triage, and more. However, for effective use, Gen AI models require significant human feedback and training using previously analyzed PV data, which companies need to take into consideration[21].
- **Digital Simulations:** Digital simulations, often computer models that predict drug behavior and AEs, can provide insights without necessitating human trials, potentially revolutionizing drug development. The pharma sector is already incorporating digital simulations in smart manufacturing efforts, reflecting the growing reliance on such technologies for predictive analysis[22]. Simulations offer the ability to predict potential AEs, which can inform important decisions like dosing recommendations.
- **Multilingual Case Processing:** Efficient case processing in multiple languages power global PV operations. Integrating translation capabilities into your PV and safety workflows meets multilingual reporting requirements, and improves signal detection to promptly identify global safety cases. In addition, multilingual case processing reduces risk when launching in a new region by meeting those translation requirements.
- **Structured Content Management:** Structured content management systems (SCMS) allow sponsors to manage vast amounts of PV data in a consistent and organized manner. An SCMS can be transformational in expediting responses to regulatory authorities, such as for PSURs and DSURs. The scope of this system enables the collection of safety reports, standardizes and structures the inbound data in alignment with international data safety standards, such as ICH E2B[23].
- **Global Submission Platforms:** Ensuring that safety data is submitted to regulatory agencies worldwide in a timely and compliant manner is essential. Global submission platforms help automate and streamline this process, reducing the risk of non-compliance and potential penalties[24].

- **PV Consulting:** PV consulting services provide expert guidance to sponsors on best practices, regulatory compliance, and strategic PV operations. By auditing and evaluating current systems, a consultant can identify opportunities for improvement and make recommendations for implementing these changes. They can provide strategic guidance on mitigating risk, managing tight turnaround times, and scalability. Leveraging such expertise empowers sponsors with the tools to optimize their PV work streams and make informed decisions that prioritize patient safety[25].
- **Automated Safety Reporting:** Integrating AI and automation in safety reporting can enhance accuracy and efficiency. Automated systems leverage algorithms with pre-defined parameters to efficiently process safety data while minimizing the risk of human errors. This level of consistency and standardization ensures timely reporting, and helps to process large volumes of data swiftly. This also upholds regulatory standards by ensuring pertinent product safety information is swiftly communicated[26].

Embracing solutions from AI and digital simulations to global submission platforms ensures not only streamlined operations but also the prioritization of patient safety. Optimizing PV and safety workflows with these technologies, positions companies at the forefront of pharmacovigilance excellence.

ROLE OF AI AND MACHINE LEARNING IN PV AND SAFETY

There are complex challenges and inefficiencies embedded in traditional, manual PV and safety processes such as case intake, triage, signal detection, and literature monitoring. Errors or inconsistencies in data entry and intensive case triage can result in delays when identifying key safety issues. Redaction tasks are often time-intensive, while AE narrative creation depends on domain knowledge and expertise, which is further complicated by subjectivity. Artificial Intelligence (AI) and Machine Learning (ML) could improve these workflows significantly.

Teams should take stock of the investment in manual activities to closely identify where this can be minimized and replaced by AI/ML tools. These include:

- **Automation of Routine Tasks:** AI can automate mundane and repetitive tasks, such as data entry and initial sorting of reports. This not only ensures accuracy but also liberates human resources to focus on more complex analytical tasks. By eliminating human intervention in routine processes, the potential for errors diminishes, leading to more reliable and efficient PV operations[27].
- **Predictive Analysis:** One of AI's standout features is its ability to predict potential outcomes based on data. Within PV, this capability allows for the early detection of adverse events, providing insights even before they become widespread. With such foresight, sponsors and healthcare professionals can take preemptive measures, which significantly enhances patient safety and minimizes risks[28].
- **Natural Language Processing (NLP):** NLP, a subset of AI, understands and processes human language from various sources like electronic health records, physician notes, or patient feedback. In PV, NLP can scan vast amounts of unstructured data to detect potential adverse events or safety concerns, ensuring critical information is not overlooked[29].

- **Signal Detection:** AI algorithms can continuously monitor vast datasets for patterns or 'signals' indicating potential new adverse events or a change in the frequency of known events. Early signal detection can lead to faster regulatory actions, such as label changes or even product recalls, which safeguards public health[30].
- **Data Integration and Harmonization:** AI can collate and harmonize data from disparate sources, ensuring a unified view of safety information. Given that PV data comes from multiple channels like clinical trials, post-marketing surveillance, and real-world evidence, AI's capability to integrate this data is invaluable for comprehensive safety assessments[31].
- **Image Recognition:** Advanced AI models can analyze medical images to detect potential signs of drug-induced injuries or conditions. This can be particularly useful in monitoring the long-term safety of therapies[32].
- **Real-time Reporting and Alerts:** ML algorithms enable real-time monitoring of safety data. Any anomalies or potential safety concerns can trigger instant alerts, ensuring immediate attention and timely interventions.

Harnessing the transformative power of AI and ML can improve PV and safety workflows and leave a lasting impact on operations, finances, and ultimately patient safety. For sponsors, PV strategies that integrate AI and ML can not only improve compliance but also lead the way in patient safety and industry excellence[33, 34].



TECHNOLOGY PLATFORMS FOR STRATEGIC INTEGRATIONS

There are complex challenges and inefficiencies embedded in traditional, manual PV and The globalization of pharmacovigilance demands integrated translation capabilities, and translation technology that is interoperable, scalable, and reduces complexity and risk. Operating on an international scale, launching products in different markets, and conducting research initiatives in different languages generates a vast quantity of multilingual safety data. Parsing this immense volume can present detrimental challenges to timely reporting, due to the added translation requirements. When operating under already stringent timelines, there is seldom time to waste in addressing the translation question.

The strategic incorporation of a Translation Management System (TMS) is key to managing this scope of translation requirements. A TMS can bridge linguistic gaps, harmonize data, and ensure that regulatory standards are met when taking the source to the target language. While saving on time, financial, and resource investments in both short- and long-term capacities, a TMS integration also facilitates the ability to safeguard the well-being of patients worldwide. As part of a successful TMS framework, the following tools should be considered when integrating:

- **Content Management Systems (CMS):** A CMS is pivotal for PV and safety due to its ability to facilitate structured storage and retrieval of vast amounts of data. This platform plays a vital role in safety writing activities, such as submitting Periodic Safety Update Reports (PSUR) and Development Safety Update Reports (DSUR) to the relevant authority. With a litany of capabilities, including version tracking, audit trails, and collaborative tools, the functionality of a CMS ensures safety data is securely stored in a central repository for enhanced visibility and quality assurance. [35]
- **eClinical Solutions:** These platforms manage and analyze clinical data, offering a unified approach to data management, reporting, and analysis. Integrating a TMS with eClinical technology ensures that clinical data, especially safety and adverse event data, is captured, processed, and reported efficiently, which reduces the risk of errors and ensures timely regulatory submissions.
- **Safety Database Integrations:** Widely recognized in the realm of PV, safety databases from companies such as Argus, Aris Global, and Veeva offer comprehensive pharmacovigilance to ensure patient safety. These connectors provide tools for the intake, triage, assessment, and reporting of safety data, which ensures compliance with global regulations.

- **MedDRA (Medical Dictionary for Regulatory Activities):** MedDRA is the international medical terminology developed under the auspices of the International Council for ICH. For PV activities, consistent terminology is imperative. MedDRA facilitates the classification of adverse events, ensuring uniformity in safety data reporting. A robust platform should have the ability to seamlessly align with MedDRA guidelines, centralizing efforts to ensure compliance.
- **Natural Language Processing (NLP):** With the integration of AI in PV workflows, NLP tools can help in the automatic extraction of relevant information from unstructured data sources. This becomes especially pertinent when analyzing patient narratives or physician notes for adverse event detection.
- **Blockchain:** While still in nascent stages for PV, blockchain technology offers potential advantages in terms of data integrity, traceability, and security. It could revolutionize the way safety data is stored and shared, ensuring transparency and tamper-proof records.
- **Integrated Data Platforms:** Given the multifaceted nature of PV data sources, ranging from clinical trials to post-marketing surveillance, integrated data platforms can collate data from various sources into a unified database, facilitating easier analysis and reporting.

Utilizing a comprehensive suite of tools, from Content Management Systems to innovative solutions like Natural Language Processing and blockchain, ensures timely, efficient, and compliant safety reporting, safeguarding patient well-being across international borders. The integration of a robust Translation Management System (TMS) with various technological platforms is paramount for seamless translation and management of multilingual safety data.

CONCLUSION

The pharmaceutical domain is complex, with patient safety and product quality as its pillars. Alongside the growing demand for medical research and innovation on a global scale, it is critical that teams stay focused on the constantly evolving technology that can advance these goals more swiftly. Leveraging the optimal technology stack empowers pharmaceutical organizations with the tools to meet and exceed reporting requirements and expectations.

Subsequently, the care and consideration applied to a PV and safety framework strategy can culminate in an impressive reputational standing with regulatory bodies, patients, and healthcare providers. This further positions organizations as leaders in defining and enforcing product safety standards. By adopting a proactive, informed PV and safety strategy, companies can realize the transformative potential of technology. To overcome common challenges and meet tight deadlines with high quality, safety teams should automate where possible, minimize errors, and combine human expertise with automation.

Adopting the best practices from this whitepaper prepares companies and sponsors to efficiently manage large volumes of case reports and ensure timely reporting to authorities. In maximizing this time to report, organizations can enhance compliance, meet deadlines, and continue to uphold patient safety standards for optimal health outcomes.

REFERENCES

[1, 2, 3, 11, 12, 15, 16, 20, 21, 22, 28, 31, 33, 35] McKinsey & Company. (2023). McKinsey Exec on Generative AI in R&D And Pharmacovigilance, Digital Twins. https://scrip.citeline.com/SC148826/McKinsey-Exec-On-Generative-AI-in-RD-And-Pharmacovigilance-Digital-Twins

[4, 13, 14, 27, 34] World Health Organization. (2023) Pharmacovigilance https://www.who.int/teams/regulation-prequalification/regulation-and-safety/pharmacovigilance

[5] McKinsey & Company. (2021). How pharma manufacturers can enhance their medical information teams. https://www.mckinsey.com/industries/life-sciences/our-insights/how-pharma-manufacturers-can-enhance-their-medical-information-teams

[6, 8] McKinsey & Company. (2022). Emerging from disruption: the future of pharma operations strategy. https://www.mckinsey.com/capabilities/operations/our-insights/emerging-from-disruption-the-future-of-pharma-operations-strategy

[7, 17, 29] Unlocking the power of Pharmacovigilance* an adaptive approach to ... - PWC. (n.d.). https://www.pwc.com/il/he/publications/assets/10unlocking_the_power.pdf

[9, 19, 30] Deloitte. (n.d.). Transforming pharmacovigilance Using technology and analytics to enable next generation patient safety. https://www2.deloitte.com/content/dam/Deloitte/us/Documents/life-sciences-health-care/us-lshc-transforming-pharmacovigilance.pdf

[10, 18, 32] Local Literature Monitoring. (2023). TransPerfect Life Sciences. https://lifesciences.transperfect.com/local-literature-monitoring

[23] European Medicines Agency. (2022, November 10). ICH E2B (R3) electronic transmission of individual case safety reports (ICSRs) - data elements and message specification implementation guide scientific guideline European Medicines Agency. European Medicines Agency. https://www.ema.europa.eu/en/ich-e2b-r3-electronic-transmission-individual-case-safety-reports-icsrs-data-elements-message

[24, 25, 26] Lucas, S., Ailani, J., Smith, T. R., Abdrabboh, A., Xue, F., & Navetta, M. S. (2022). Pharmacovigilance: reporting requirements throughout a product's lifecycle. Therapeutic advances in drug safety, 13, 20420986221125006. https://doi.org/10.1177/20420986221125006